GlassScriptPhysician profile
Katherine M Bear
NPI 1245863786
$1,267.92
in general payments reported to CMS, 2019-2025
19 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $47.62 · 2023: $418 · 2024: $362 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Entertainment: $13.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.72 |
| Entertainment | $13.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196.96 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $195.23 | 2023-2024 | Xarelto, Invega, Spravato |
| Indivior INC. | $126.49 | 2023-2024 | Sublocade |
| Actelion Pharmaceuticals US, INC. | $114.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $98.73 | 2022-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $86.75 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Braeburn INC. | $79.61 | 2023-2024 | Brixadi |
| Alkermes, INC. | $63.91 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $59.90 | 2025 | Rexulti |
| Corium, LLC | $46.78 | 2024-2025 | Azstarys |
| Organon LLC | $32.07 | 2023 | Nexplanon |
| Abbott Laboratories | $30.93 | 2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $26.99 | 2024 | Ingrezza |
| Hologic Sales and Service, LLC | $24.67 | 2025 | Aptima, Thinprep 2000 Processor |
| Supernus Pharmaceuticals, INC. | $23.65 | 2025 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $16.90 | 2025 | Fanapt |
| Lilly USA, LLC | $16.17 | 2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.60 | 2023 | |
| Optos, INC. | $13.43 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Bear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.